Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects With Metastatic Malignant Melanoma

Phase 2

Completed

• Conditions: Melanoma; Neoplasm Metastasis

• Registration Number: NCT00055562
• Lead Sponsor: Celgene Corporation

Brief Summary

Subjects are randomized to one of two treatment arms. All subjects are screened for eligibility within 28 days prior to randomization. The study consists of a treatment phase and a follow-up phase. Subjects will be treated in repeating 4 week cycles.

Detailed Description

Not available

Study Timeline

• Study Start: 2003-01
• Study First Submitted: 2003-03-05
• Study First Submitted QC: 2003-03-05
• Study First Posted: 2003-03-06
• Status Verified: 2004-05
• Study Completion: 2004-12
• Last Update Submitted: 2005-06-23
• Last Update Posted: 2005-06-24

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 274

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Trial Locations

Locations (31)

University of Arizona Cancer Center; 🇺🇸 Tucson, Arizona, United States

University of Southern California Norris Cancer Center; 🇺🇸 Los Angeles, California, United States

UCLA; 🇺🇸 Los Angeles, California, United States

St. Francis Memorial Hospital; 🇺🇸 San Francisco, California, United States

Outpatient Clinic; 🇺🇸 Santa Monica, California, United States

University of Colorado; 🇺🇸 Aurora, Colorado, United States

The Harold Lever Regional Cancer Center; 🇺🇸 Waterbury, Connecticut, United States

Lakeland Regional Cancer Center; 🇺🇸 Lakeland, Florida, United States

Mount Sinai Comprehensive Cancer Center; 🇺🇸 Miami Beach, Florida, United States

Lutheran General; 🇺🇸 Park Ridge, Illinois, United States

Scroll for more (21 remaining)